VIVUS Revenue and Competitors
Estimated Revenue & Valuation
- VIVUS's estimated annual revenue is currently $36.4M per year.
- VIVUS received $200.0M in venture funding in May 2013.
- VIVUS's estimated revenue per employee is $251,250
- VIVUS's total funding is $53.6M.
Employee Data
- VIVUS has 145 Employees.
- VIVUS grew their employee count by 5% last year.
VIVUS's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CEO | Reveal Email/Phone |
2 | VP, Chief Commercial Officer | Reveal Email/Phone |
3 | VP, Business Analytics & Digital Marketing | Reveal Email/Phone |
4 | VP, North America Sales | Reveal Email/Phone |
5 | VP, Business Development | Reveal Email/Phone |
6 | VP, Marketing and Commercial Operations North America | Reveal Email/Phone |
7 | Associate Director, Commercial & HCP Compliance | Reveal Email/Phone |
8 | Associate Director, Clinical Operations | Reveal Email/Phone |
9 | Director, Market Access | Reveal Email/Phone |
10 | President VIVUS Global Pharmaceutical Development & Chief Medical Officer | Reveal Email/Phone |
VIVUS Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is VIVUS?
With demonstrated clinical development and commercialization expertise, VIVUS is dedicated to addressing the therapeutic needs of patients with serious medical conditions and life-limiting diseases. We develop high-potential molecules that have compelling safety and efficacy potential, and transform them into proprietary products that enable significant advances in patient care and outcomes. We strive to meet our goals of improving patient quality of life, giving healthcare providers new treatment options, providing a collaborative environment for our employees and creating value for our shareholders.
keywords:Biotechnology,Healthcare,Medical Devices,Pharmaceuticals
$53.6M
Total Funding
145
Number of Employees
$36.4M
Revenue (est)
5%
Employee Growth %
N/A
Valuation
N/A
Accelerator
VIVUS News
... Market 2022-2028 Trends with respect to Regions and Top Players: GSK (GlaxoSmithKline), Nutrisystem, Atkins Nutritionals, Vivus.
Ltd, Teva Pharmaceutical Industries Ltd, and VIVUS Inc. The report provides a good overview of the key macroeconomic factors that have a...
VIVUS Inc; Sanofi; Menarini Group; Auxilium Pharmaceuticals; Endo International; JW Pharmaceutical. This record is divided into numerous...
Share Share on Facebook Share on Twitter LinkedIn Email Reprints Vivus (NASDAQ: VVUS), the Mountain View, CA-based based obesity drug developer, said today it has submitted a briefing document to the FDA to answer questions the agency raised when it turned down the company’s new drug applicatio ...
Vivus, a publicly traded Mountain View drug developer focused on obesity and sexual health, received $33.6 million in private equity financing, after the company announced deepening losses. Caxton Advantage Life Sciences Fund led the financing. Also participating were Franklin Templeton Investm ...
Other Companies in Campbell
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $23.1M | 150 | -2% | N/A |
#2 | $51.7M | 162 | 5% | N/A |
#3 | $26M | 173 | 9% | $518M |
#4 | $25.5M | 178 | -2% | N/A |
#5 | $40.7M | 178 | -5% | N/A |
VIVUS Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2003-05-29 | $17.5M | Private Placement | Article | |
| 2007-08-10 | $140.0M | Undisclosed | KV Pharmaceutical | Article |
| 2008-08-06 | $65.0M | Undisclosed | Trout Capital LLC | Article |
| 2009-09-18 | $94.5M | Undisclosed | J P Morgan Securities Inc | Article |
| 2009-09-25 | $108.7M | Undisclosed | Merriman Curhan Ford Group In | Article |
| 2011-08-24 | $45.8M | Undisclosed | QVT Financial LP | Article |
| 2012-02-29 | $Undisclosed | Undisclosed | J P Morgan Securities LLC | Article |
| 2013-03-27 | $110.0M | Undisclosed | Pharmakon Advisors | Article |
| 2013-05-16 | $200.0M | Undisclosed | Article |